[The rates of seropositivity and seroconversion of toxoplasma infection in pregnant women].
Infections caused by Toxoplasma gondii are frequently asymptomatic in healthy adults, however they may be serious in pregnant women and immunocompromised patients. The aims of this study were to investigate the rates of seropositivity and seroconversion in pregnant women and newborn cord blood samples, and to evaluate those data in the view of relation to lifestyle and nutrition. A total of 312 pregnant women (mean age: 28.1 ± 5.2 years) who were admitted to and followed by gynecology clinics of Inonu University Medical School Hospital, Malatya, Turkey were included in this observational and cross-sectional study. Anti-toxoplasma IgG and IgM antibodies in pregnants and newborn cord sera were screened by commercial ELISA and immunofluorescence antibody (BioTek; USA) methods. A total of 312 sera from pregnant women and 312 cord blood samples during delivery were collected. IgG seropositivity rate in pregnants was found as 37.5% (117/312), seroconversion was not determined in restrained pregnants and T.gondii IgM was found negative in all pregnants. Also in all newborns IgM was negative and IgG seropositivity was determined as 33.3% (104/312) in cord blood. There was a statistically significant relationship between IgG seropositivity and raw meat consumption (p< 0.001) and being engaged in agriculture (p< 0.005). It was concluded that toxoplasma antibodies should routinely be searched on the first visit of the pregnants and the seronegative cases should be trained about the preventive measures related to toxoplasmosis. The follow-up of toxoplasma seronegative cases during pregnancy can be achieved by only detecting the IgM class antibodies and this will also reduce the cost of screen test.
İstanbul Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Department of Obstetrics, İstanbul, Turkey.
Keziban
K
Doğan
Ayşe
A
Kafkaslı
Ulkü
U
Karaman
Metin
M
Atambay
Leyla
L
Karaoğlu
Cemil
C
Colak
D000328:Adult; D000913:Antibodies, Protozoan / Q000097:blood*; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000453:epidemiology* / Q000276:immunology; D012307:Risk Factors; D014122:Toxoplasma / Q000276:immunology*; D014123:Toxoplasmosis / Q000453:epidemiology* / Q000276:immunology / Q000635:transmission; D014125:Toxoplasmosis, Congenital / Q000453:epidemiology / Q000276:immunology; D014421:Turkey / Q000453:epidemiology
D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D007075:Immunoglobulin M